Weekly Update: September 5 to September 16, 2022.
The analysis is updated every two weeks.
| ACTIV-3/TICO Study Group, Ann Intern Med, 2022 |
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. |
| Adhikari P, Int. J. Infect. Dis, 2022 |
Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial |
| Arruda E A G, medrxiv, 2021 |
Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections |
| Audemard-Verger A, PloS one, 2022 |
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial. |
| Corvus Pharmaceuticals, Inc. |
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients |
| Evering TH, Open Forum Infect. Dis., 2021 |
Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients |
| Fortunez PR, Basic Clin. Pharmacol. Toxicol., 2022 |
Safety of the use of methylprednisolone pulses versus dexamethasone in patients with pneumonia due to SARS-CoV-2 infection: preliminary results |
| Gusdon AM, Sci Transl Med, 2022 |
Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. |
| Hooper AT, medrxiv, 2022 |
Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies |
| Jilg N, Top. antivir. Med, 2022b |
CAMOSTAT IS NOT EFFECTIVE for MILD-MODERATE COVID-19 in A PHASE 2 TRIAL of ACTIV-2 |
| Johnson MG, Ann Intern Med, 2022 |
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. |
| Johnston C, Unpublished, 2022 |
Treatment for SARS-CoV-2 in High-Risk Adult Outpatients |
| Khoo SH, medRxiv, 2022 |
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2 |
| Montejano R, Clin Infect Dis, 2022 |
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe COVID-19: The PANCOVID Randomized Clinical Trial. |
| NCT04590586, Unpublished, 2022 |
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients |
| Siami Z, Iran. Red Crescent Med. J, 2022 |
Efficacy and safety of atazanavir/ritonavir versus lopinavir/ritonavir in hospitalized COVID-19 patients: a randomized clinical trial |
| Sirijatuphat R, Emerg Microbes Infect, 2022 |
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study |
| Sivapalasingam |
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia |
| Taiwo BO, Top. antivir. Med, 2022 |
PHASE-2 STUDY of SAB-185, A POLYCLONAL ANTIBODY TREATMENT for COVID-19 in ACTIV-2 |
| Troseid M, SSRN, 2022 |
Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial |
| Yakoot M, medRxiv, 2022 |
Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study |
| Zou R, Front Pharm, 2022 |
Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. |
| Achiron A, J Neurol, 2022 |
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. |
| Al Kaabi N, medRxiv, 2022 |
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial |
| Anderson E, Research Square, 2022 |
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine An Interim Analysis |
| Barrios L, , medRxiv, 2022 |
An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study |
| Branche AR, medRxiv, 2022 |
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses |
| Bruminhent J, Am J Transplant, 2022 |
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: a randomized controlled trial (CVIM 4 study). |
| Corominas J, medRxiv, 2022 |
Safety and immunogenicity of the protein-based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. |
| Costa Clemens SA, medrxiv, 2022 |
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study |
| El Sahly HM, J Infect Dis, 2022 |
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial. |
| Fadlyana E, SSRN, 2022 |
Immunogenicity and Safety in Healthy Adults of Full-Dose Versus Half Doses of COVID-19 Vaccine (ChAdOx1-S or BNT162b2) or Full-Dose CoronaVac Administered as a Booster Dose after Priming with Coronavac: A Randomized, Observer-Blinded, Contr |
| Hernandez-Bernal F, SSRN, 2022 |
A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial for Adult Evaluation of the Efficacy and Safety of a Sars-Cov-2 Recombinant Spike Rbd Protein Vaccine (Abdala-3 Study) |
| Jin P, medrxiv, 2022 |
Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study |
| Kelliher MT, Arch Pathol Lab Med, 2022 |
Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. |
| Kulkarni PS, SSRN, 2022 |
Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study |
| LAUNAY O, medrxiv, 2022 |
Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine |
| Lien CE, SSRN, 2022 |
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults |
| Madhi SA, Lancet, 2022 |
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. |
| Nantanee R, Vaccine, 2022 |
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. |
| Niyomnaitham S, Hum Vaccin Immunother, 2022 |
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adul |
| Puthanakit T; Vaccine: X; 2022 |
Heterologous Prime-boost of SARS-CoV-2 Inactivated Vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. |
| Rose W, SSRN, 2022 |
Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN®) in Previous Recipients of COVISHIELDTM or COVAXIN®: A Phase 4, Participant and Observer Blinded, Randomis |
| Sung JC, Vaccines, 2022 |
Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines. |
| Tabarsi P, Immunology, 2022 |
Immunogenicity and Safety of SpikoGen®, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein vaccine as a Homologous and Heterologous Booster Vaccination: A Randomized Placebo-Controlled Trial. |
| Thuluva S, medRxiv, 2022 |
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies |
| Zeng G, Lancet Infect Dis, 2021 |
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials |
| Zhu F, Lancet Respir Med, 2022 |
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. |
34 early phase vaccine trials where the vaccine dose and schedule have not yet been determined :
| Abarca K, Vaccines, 2022 |
Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial. |
| Angkasekwinai N, Vaccine, 2021 |
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| Anh DD, SSRN, 2022 |
Safety and Immunogenicity of an Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam |
| Butta N, SSRN, 2022 |
Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS Study |
| Cao Y, Sci China Life Sci, 2022 |
A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial. |
| Chen GL, Lancet microbe, 2022 |
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial |
| Chen J, 2021 |
[A randomized controlled trial study of immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in different immunization schedules]. |
| Chiuppesi F, Lancet Microbe, 2022 |
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. |
| Dang AD, medrxiv, 2022 |
Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam |
| Follmann D, Ann Intern Med, 2022 |
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. |
| Garcia-Perez J, eClinicalMedicine, 2022 |
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. |
| Iwata S, SSRN, 2022 |
Phase 1/2 Clinical Trial of COVID-19 Vaccine in Japanese Participants: A Report of Interim Findings |
| Launay O, EBioMedicine, 2022 |
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. |
| Marchevsky NG, eBioMedicine, 2022 |
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. |
| Mohraz M, BMJ Open, 2022 |
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. |
| Mohraz M, BMJ Open, 2022 |
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. |
| Orozco MN, medrxiv, 2022 |
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B |
| Pajon R, Nat Med, 2022 |
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. |
| Pitisuttithum P, EClinicalMedicine, 2022 |
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. |
| Pollock KM, eclinicalmedicine, 2022 |
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial |
| Robbins JA, eBioMedicine, 2022 |
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. |
| Robbins JA, eBioMedicine, 2022 |
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. |
| Saez-Llorens X , SSRN, 2021 |
Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study |
| Song JY , medrxiv, 2022 |
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial |
| Song JY, EClinicalMedicine, 2022 |
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. |
| Tabarsi P, CMI, 2022 |
Safety and immunogenicity of SpikoGen®, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. |
| Tanishima M, medRxiv, 2022 |
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan |
| Tanishima M, medRxiv, 2022 |
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan |
| Thuluva S, medRxiv, 2022 |
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies |
| Vanhoutte F, EBioMedicine, 2022 |
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial |
| Wang CY, J Clin Invest, 2022 |
A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. |
| Wynne C, medRxiv, 2022 |
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV |
| Xia S, Front Immunol, 2022 |
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. |
| Xia S, Front Immunol, 2022 |
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. |
These interventions were not prioritized but they might be included in the future. Details here